Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

December 1, 2011

Study Completion Date

December 14, 2011

Conditions
Asthma
Interventions
DRUG

Placebo

Placebo matching fluticasone propionate HFA MDI

DRUG

Fluticasone propionate

Fluticasone propionate HFA MDI

DRUG

BI 54903

BI 54903 via Respimat inhaler

Trial Locations (37)

Unknown

1248.7.01047 Boehringer Ingelheim Investigational Site, Fountain Valley

1248.7.01023 Boehringer Ingelheim Investigational Site, Fullerton

1248.7.01038 Boehringer Ingelheim Investigational Site, Long Beach

1248.7.01004 Boehringer Ingelheim Investigational Site, Mission Viejo

1248.7.01028 Boehringer Ingelheim Investigational Site, Palmdale

1248.7.01044 Boehringer Ingelheim Investigational Site, Stockton

1248.7.01015 Boehringer Ingelheim Investigational Site, Centennial

1248.7.01035 Boehringer Ingelheim Investigational Site, Aventura

1248.7.01022 Boehringer Ingelheim Investigational Site, Miami

1248.7.01051 Boehringer Ingelheim Investigational Site, Columbus

1248.7.01052 Boehringer Ingelheim Investigational Site, Savannah

1248.7.01011 Boehringer Ingelheim Investigational Site, Eagle

1248.7.01055 Boehringer Ingelheim Investigational Site, Oak Lawn

1248.7.01019 Boehringer Ingelheim Investigational Site, Baltimore

1248.7.01039 Boehringer Ingelheim Investigational Site, North Dartmouth

1248.7.01037 Boehringer Ingelheim Investigational Site, Ypsilanti

1248.7.01056 Boehringer Ingelheim Investigational Site, Rolla

1248.7.01036 Boehringer Ingelheim Investigational Site, Warrensburg

1248.7.01020 Boehringer Ingelheim Investigational Site, Omaha

1248.7.01049 Boehringer Ingelheim Investigational Site, Berlin

1248.7.01026 Boehringer Ingelheim Investigational Site, Ocean City

1248.7.01054 Boehringer Ingelheim Investigational Site, Trenton

1248.7.01031 Boehringer Ingelheim Investigational Site, High Point

1248.7.01045 Boehringer Ingelheim Investigational Site, Cincinnati

1248.7.01021 Boehringer Ingelheim Investigational Site, Portland

1248.7.01013 Boehringer Ingelheim Investigational Site, Philadelphia

1248.7.01040 Boehringer Ingelheim Investigational Site, Pittsburgh

1248.7.01012 Boehringer Ingelheim Investigational Site, Upland

1248.7.01048 Boehringer Ingelheim Investigational Site, Charleston

1248.7.01050 Boehringer Ingelheim Investigational Site, Austin

1248.7.01002 Boehringer Ingelheim Investigational Site, Live Oak

1248.7.01032 Boehringer Ingelheim Investigational Site, San Antonio

1248.7.01046 Boehringer Ingelheim Investigational Site, San Antonio

1248.7.01001 Boehringer Ingelheim Investigational Site, Waco

1248.7.01025 Boehringer Ingelheim Investigational Site, Murray

1248.7.01053 Boehringer Ingelheim Investigational Site, Alexandria

1248.7.01030 Boehringer Ingelheim Investigational Site, Tacoma

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01396278 - Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). | Biotech Hunter | Biotech Hunter